Evaluation of molecular biomarkers for hepatocellular carcinoma (HCC) therapy

Not Applicable

Recruiting

• Conditions: Liver Cancer; Hepatocellular Carcinoma; Liver Cirrhosis; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Cancer - Liver

• Registration Number: ACTRN12623000762651
• Lead Sponsor: A/Prof Adam Testro

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-12
• Last Update Posted: 18 July 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Study question 1:
1.Age 18 or greater
2.Adult patients undergoing therapy for Hepatocellular Carcinoma (HCC)
a.Therapy may include 3 broad categories
i.Interventional radiology
1.Transarterial Chemo-embolisaion (TACE)
2.Microwave ablation (MWA)
3.Radiofrequency ablation (RFA)
4.Selective Internal Radiation-Therapy (SIRT)
5.Percutaneous Ethanol Injection (PEI)
ii.Surgery
1.Liver resection
2.Liver transplantation
iii.Radiation oncology
1.Stereotactic Body Radiation Therapy (SBRT)
iv.Medical oncology
1.Systemic therapy
v.Other
3.Informed consent

Study Question 2:
1.Age 18 or greater
2.Adult patients diagnosed with HCC
a.Referred to the HCC Multi-disciplinary meeting for consideration of liver transplant assessment or
b.Referred to the pre-liver transplant clinic for consideration of liver transplant assessment
3.Patients must have been informed by a clinician from the Liver Transplant Unit that they are being considered for liver transplant assessment, with documentation in medical records
a.Patients may or may not yet have been formally assessed or wait listed for liver transplantation
4.Patients may or may not have undergone prior therapy for HCC
5.Informed consent

Exclusion Criteria

1.Unable to consent
2.Withdrawal of consent

Study & Design

• Study Type: Observational
• Study Design: Not specified